- Report
- August 2024
- 116 Pages
Global
From €4004EUR$4,500USD£3,514GBP
- Report
- January 2024
- 130 Pages
Global
From €4004EUR$4,500USD£3,514GBP
- Report
- July 2023
- 100 Pages
Global
From €4315EUR$4,850USD£3,788GBP
- Report
- August 2025
- 150 Pages
Global
From €2987EUR$3,358USD£2,622GBP
€3514EUR$3,950USD£3,085GBP
- Report
- November 2024
- 120 Pages
Global
From €3500EUR$4,214USD£3,180GBP
- Report
- May 2024
- 95 Pages
Global
From €3500EUR$4,214USD£3,180GBP
- Report
- February 2024
- 91 Pages
Global
From €3500EUR$4,214USD£3,180GBP
- Report
- February 2024
- 103 Pages
Global
From €3500EUR$4,214USD£3,180GBP
- Report
- February 2022
- 87 Pages
Global
From €3200EUR$3,853USD£2,907GBP
- Report
- January 2025
- 132 Pages
Global
From €845EUR$950USD£742GBP
- Report
- January 2025
- 132 Pages
Global
From €845EUR$950USD£742GBP
- Report
- January 2025
- 132 Pages
Global
From €845EUR$950USD£742GBP
- Book
- June 2020
- 198 Pages
- Report
- November 2021
- 527 Pages
Global
From €3559EUR$4,000USD£3,124GBP
- Report
- November 2021
- 802 Pages
Global
From €4449EUR$5,000USD£3,905GBP
- Report
- November 2021
- 1184 Pages
Global
From €5338EUR$6,000USD£4,686GBP
- Report
- November 2021
- 1165 Pages
Global
From €5338EUR$6,000USD£4,686GBP

The CRISPR market is a subset of the genomics market that focuses on the use of CRISPR-Cas9 technology for gene editing. CRISPR-Cas9 is a powerful tool that enables scientists to make precise changes to the genome of living organisms. This technology has been used to develop treatments for a variety of diseases, as well as to create new crops and livestock. CRISPR-Cas9 technology has also been used to create gene drives, which are designed to spread a desired trait through a population.
The CRISPR market is highly competitive, with a number of companies offering products and services related to gene editing. These companies include Editas Medicine, Intellia Therapeutics, CRISPR Therapeutics, Caribou Biosciences, and ERS Genomics. These companies are developing a range of products, from gene editing tools to gene therapies, and are working to make CRISPR-Cas9 technology more accessible and affordable. Show Less Read more